Browse list of available series in The Biomedical & Life Sciences Collection
Recommend The Biomedical & Life Sciences Collection to your librarian
Request to be kept updated on The Biomedical & Life Sciences Collection
Apply for a free trial of The Biomedical & Life Sciences Collection
View all talks & series with full access

Guest (sample access)

Optional Login with Username


        
> Home  /  Biomedical & Life Sciences  /  Series  /  Natural Killer Cell Biology  /  Talk Details
SHARE:   Email via Outlook   Email via Web   Facebook   Twitter   |   more
Close SHARE
Please select one of the methods below to share the following page with your collegues:
Natural killer cells: development, diversity and applications to human disease
Blogger Google Reader
Delicious Linked In
Digg MySpace
Favorites PDF Online
Gmail

Hello. As a guest, you do not have full access to this talk. Click the PLAY button below to watch the sample extract. Alternatively, you may login or review methods of obtaining more access.

    SPEAKER(S)

Prof. Mike Caligiuri - Ohio State University, USA

Michael Caligiuri is Director of the Comprehensive Cancer Center, CEO of the James Cancer Hospital & Solove Research Institute and JL Marakas Nationwide Insurance Enterprise Foundation Professor of Cancer Research at the Ohio State University. His laboratory focuses on research in leukemia, lymphoma and the human immune system. His current projects include developing a vaccine to prevent lymphoma in organ transplant patients, studying natural killer cell biology, and working to target genetic defects in leukemia and lymphoma for curative therapies. Caligiuri earned his graduate and medical degrees at Stanford University School of Medicine, then trained in internal medicine, oncology, bone marrow transplantation and immunology at Harvard before joining the Harvard Medical School faculty in 1989. He next spent seven years at Roswell Park Medical Center in Buffalo, NY, where he became Assistant, Associate, and Full Professor of Medicine. He was recruited to The Ohio State University in 1997 as the OSUCCC Associate Director for Clinical Research. He has more than 200 peer-reviewed publications in scientific journals and has given hundreds of lectures on his research throughout the world.

Talk Online Publication: Sep 2009

TOPICS COVERED IN NATURAL KILLER CELLS: DEVELOPMENT, DIVERSITY AND APPLICATIONS TO HUMAN DISEASE

Human NK cell development - What factors are responsible for NK cell development? - How does KL or FL assist IL-15 in NK cell development? - NK progenitor, NK precursor, mature NK cell - Only CD34dimCD45RA(+) HPC differentiate into CD56bright NK cells - NK cells are in human lymph nodes and are CD56bright - Putative stages of human NK cell differentiation in nodes/tonsils - How NK cell development fits in human lymphopoiesis - IL-15 and human NK cell survival - Adoptive transfer of NK cells into IL-15-deficient mice - IL-15 transgene - Lymphoblastic leukemia - Human NK cell subsets - Do NK cell subsets have unique immunoregulatory roles? - LPS activation - NK cell-derived IFN-γ in the innate immune response - Innate immunoregulator, CD56bright - Innate cytotoxic effector, CD56dim - How do inhibitory NKR work? - How does KIR work? - Haplo-mismatch BMT

How to cite this talk:
Caligiuri, M. (2009), "Natural killer cells: development, diversity and applications to human disease", in Lanier, L. (ed.), Natural Killer Cell Biology: Natural killer cell-mediated immunity to pathogens and cancer, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio)

Direct talk access link:
http://hstalks.com/lib.php?t=HST87.2204_1_2&c=252

    DETAILED SLIDE INDEX

1. Introduction
2. Talk outline
3. Known facts about NK cell development (1993)
4. IL-2 and IL-15 receptors
5. IL-15 induces human NK cell differentiation
6. Factors responsible for NK cells development
7. KL/FL ligands and NK cells development (1)
8. KL/FL ligands and NK cells development (2)
9. SCF, IL-2 and IL-15 in NK cell development
10. Human natural killer cell development
11. Which CD34 subset develops into a NK cell?
12. CD34 receptor expression
13. CD34 in peripheral blood and lymph nodes
14. NK precursor selectively enriched in lymph nodes
15. Site of NK cell development
16. NK cells in lymph nodes are CD56 bright cells
17. Putative stages of human NK cell differentiation
18. NK cell development in human lymphopoiesis
19. IL-15 and human NK cell survival
20. Adoptive transfer of NK cells
21. IL-15 is required for NK cell survival in vivo
22. IL-15 and NK cell development and survival
23. The IL-15 transgene
24. NK cell expansion in IL-15tg mice
25. IL-15tg mice clinical signs and findings
26. Acute T-NK lymphoblastic leukemia
27. NK cell maturation
28. NK cell subsets
29. The immunoregulatory role of NK cell subsets
30. Where does the INF-gamma signal come from?
31. Macrophage and NK co-culture: LPS activation (1)
32. NK cell-derived IFN-gamma
33. Macrophage and NK co-culture: LPS activation (2)
34. Bright cells are the primary source of IFN-gamma
35. IFN-gamma production in bright and dim cells
36. CD56 bright NK cells in the immune response
37. Innate immunoregulator, CD56 bright
38. Innate cytotoxic effector, CD56 dim
39. How do inhibitory NKR work? (1)
40. How does KIR work?
41. How do Inhibitory NKR work? (2)
42. The inhibitory receptors bind to specific epitopes
43. Common epitopes that bind to these receptors
44. Haplo-mismatch bone marrow transplant (BMT)
45. Haplo-mismatch BMT that results in lysis
46. Haplo-mismatch BMT that results in no lysis
47. Haplo-mismatch BMT - no lysis outcome
48. Summary of haplo-mismatch BMT
49. KIR mismatch/ no mismatch
50. Conclusions
51. Summary
52. Acknowledgments
53. END